Immuneering Corporation Deferred Income Tax Expense (Benefit)
Immuneering Corporation (IMRX) reported Deferred Income Tax Expense (Benefit) of -$307.49 thousand for the 12-month period ending 2021-12-31, per its 10-K filed 2023-03-06.
Discontinued › Cash Flow
us-gaap:DeferredIncomeTaxExpenseBenefit · last filed 2023-03-06
- Immuneering Corporation deferred income tax expense (benefit) for fiscal 2021 was -$307.49K.
| Period end | Deferred Income Tax Expense (Benefit) 12 month |
|---|---|
| 2021-12-31 | -$307.49K 10-K · filed 2023-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |